JP2014504270A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014504270A5 JP2014504270A5 JP2013537908A JP2013537908A JP2014504270A5 JP 2014504270 A5 JP2014504270 A5 JP 2014504270A5 JP 2013537908 A JP2013537908 A JP 2013537908A JP 2013537908 A JP2013537908 A JP 2013537908A JP 2014504270 A5 JP2014504270 A5 JP 2014504270A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- receptor
- fusion protein
- integrin
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41135010P | 2010-11-08 | 2010-11-08 | |
| US61/411,350 | 2010-11-08 | ||
| PCT/US2011/059599 WO2012064658A1 (en) | 2010-11-08 | 2011-11-07 | Fusion proteins comprising an engineered knottin peptide and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017079525A Division JP6535361B2 (ja) | 2010-11-08 | 2017-04-13 | 改変ノッチンペプチドを含む融合タンパク質及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014504270A JP2014504270A (ja) | 2014-02-20 |
| JP2014504270A5 true JP2014504270A5 (https=) | 2014-12-25 |
| JP6170435B2 JP6170435B2 (ja) | 2017-07-26 |
Family
ID=46051256
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013537908A Expired - Fee Related JP6170435B2 (ja) | 2010-11-08 | 2011-11-07 | 改変ノッチンペプチドを含む融合タンパク質及びその使用 |
| JP2017079525A Expired - Fee Related JP6535361B2 (ja) | 2010-11-08 | 2017-04-13 | 改変ノッチンペプチドを含む融合タンパク質及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017079525A Expired - Fee Related JP6535361B2 (ja) | 2010-11-08 | 2017-04-13 | 改変ノッチンペプチドを含む融合タンパク質及びその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US10844106B2 (https=) |
| EP (2) | EP3604549A1 (https=) |
| JP (2) | JP6170435B2 (https=) |
| AU (3) | AU2011326164B2 (https=) |
| CA (1) | CA2817197C (https=) |
| DK (1) | DK2638173T3 (https=) |
| WO (1) | WO2012064658A1 (https=) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008045252A2 (en) * | 2006-10-04 | 2008-04-17 | The Board Of Trustees Of The Leland Stanford Junior University | Engineered integrin binding peptides |
| US10844106B2 (en) | 2010-11-08 | 2020-11-24 | The Board Of Trustees Of The Leland Stanford Junior University | Fusion proteins comprising an engineered knottin peptide and uses thereof |
| WO2013078250A2 (en) | 2011-11-22 | 2013-05-30 | The Board Of Trustees Of The Leland Stanford Junior University | Cystine knot peptides that bind alpha-v-beta-6 integrin |
| US9844582B2 (en) | 2012-05-22 | 2017-12-19 | Massachusetts Institute Of Technology | Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents |
| US9587001B2 (en) | 2012-10-19 | 2017-03-07 | The Board Of Trustees Of The Leland Stanford Junior University | Conjugated knottin mini-proteins containing non-natural amino acids |
| CA2913029A1 (en) * | 2012-12-10 | 2014-06-19 | Fred Hutchinson Cancer Research Center | Lipocalin fusion partners |
| CA2894539C (en) | 2012-12-14 | 2021-09-28 | The Board Of Trustees Of The Leland Stanford Junior University | Modified axl peptides and their use in inhibition of axl signaling in anti-metastatic therapy |
| US11559580B1 (en) | 2013-09-17 | 2023-01-24 | Blaze Bioscience, Inc. | Tissue-homing peptide conjugates and methods of use thereof |
| WO2016025647A1 (en) | 2014-08-12 | 2016-02-18 | Massachusetts Institute Of Technology | Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine |
| CA2957717C (en) * | 2014-08-12 | 2021-10-19 | Massachusetts Institute Of Technology | Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein |
| CN107847554A (zh) * | 2015-06-26 | 2018-03-27 | 弗莱德哈钦森癌症研究中心 | 治疗性肽及其使用方法 |
| WO2017044894A2 (en) | 2015-09-09 | 2017-03-16 | Fred Hutchinson Cancer Research Center | Cartilage-homing peptides |
| TWI799366B (zh) | 2015-09-15 | 2023-04-21 | 美商建南德克公司 | 胱胺酸結骨架平臺 |
| JP7308505B2 (ja) * | 2016-01-08 | 2023-07-14 | マキシオン セラピューティクス リミテッド | 多様性を変化させた足場ドメインを有する結合メンバー |
| US10888603B2 (en) * | 2016-02-12 | 2021-01-12 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating cancer cells expressing tumor-associated integrins |
| US10765625B2 (en) | 2016-03-15 | 2020-09-08 | The Board Of Trustees Of The Leland Stanford Junior University | Knottin-drug conjugates and methods of using the same |
| WO2018044234A1 (en) * | 2016-08-31 | 2018-03-08 | Nanyang Technological University | Cysteine-rich polypeptides and conjugates and methods of using the same |
| AU2018207303A1 (en) | 2017-01-10 | 2019-07-25 | xCella Biosciences, Inc. | Combination tumor treatment with an integrin-binding-Fc fusion protein and immune modulator |
| US10350266B2 (en) | 2017-01-10 | 2019-07-16 | Nodus Therapeutics, Inc. | Method of treating cancer with a multiple integrin binding Fc fusion protein |
| WO2018136614A1 (en) | 2017-01-18 | 2018-07-26 | Fred Hutchinson Cancer Research Center | Peptide compositions and methods of use thereof for disrupting tead interactions |
| EP3595699A4 (en) | 2017-03-16 | 2020-12-23 | Blaze Bioscience, Inc. | PEPTIDIC CONJUGATES OF CARTILAGE ECOTROPISM AND THEIR METHODS OF USE |
| EP3638290A4 (en) | 2017-06-15 | 2021-04-07 | Blaze Bioscience, Inc. | KIDNEY HOMING PEPTIDE CONJUGATES AND METHOD OF USING THEREOF |
| GB201711208D0 (en) | 2017-07-12 | 2017-08-23 | Iontas Ltd | Ion channel inhibitors |
| EP3658186A4 (en) * | 2017-07-24 | 2020-08-12 | Rutgers, The State University of New Jersey | FUSION MOLECULES TARGETING PHOSPHATIDYLSERINE AND THEIR METHODS OF USE |
| CA3086040A1 (en) | 2017-12-19 | 2019-06-27 | Blaze Bioscience, Inc. | Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof |
| EP3914289A1 (en) | 2019-01-23 | 2021-12-01 | Massachusetts Institute of Technology | Combination immunotherapy dosing regimen for immune checkpoint blockade |
| CN113661240B (zh) * | 2019-04-02 | 2024-11-05 | 伊莱利利公司 | 选择和检测结合肽的方法 |
| EP3962511A4 (en) * | 2019-04-29 | 2023-01-18 | The Board of Trustees of the Leland Stanford Junior University | METHODS OF OCULAR TREATMENT USING A GENETICALLY MODIFIED HEPATOCYTE GROWTH FACTOR DIMERIC FRAGMENT |
| JP2022533671A (ja) * | 2019-05-22 | 2022-07-25 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 薬物複合体およびその使用方法 |
| AU2020357806A1 (en) * | 2019-09-30 | 2022-05-26 | The Board Of Trustees Of The Leland Stanford Junior University | Knottin-immunostimulant conjugates and related compositions and methods |
| WO2022026906A2 (en) * | 2020-07-30 | 2022-02-03 | The Board Of Trustees Of The Leland Stanford Junior University | Lysosomal targeting molecules comprising knottin peptides and related compositions and methods |
| MX2020012914A (es) * | 2020-11-27 | 2022-05-30 | Centro De Investig Cientifica Y De Educacion Superior De Ensenada Baja California Cicese | Proteina andamio para la generacion de proteinas quimericas de union a antigeno. |
| WO2025255080A1 (en) * | 2024-06-04 | 2025-12-11 | The Children's Hospital Of Philadelphia | Hypoxia inducible high-fidelity circuit |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5468634A (en) * | 1991-06-24 | 1995-11-21 | The University Of North Carolina At Chapel Hill | Axl oncogene |
| US6699658B1 (en) | 1996-05-31 | 2004-03-02 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| US6303749B1 (en) * | 1999-01-29 | 2001-10-16 | Amgen Inc. | Agouti and agouti-related peptide analogs |
| DE10053224A1 (de) | 2000-10-26 | 2002-05-08 | Univ Goettingen Georg August | Verfahren zur Exposition von Peptiden und Polypeptiden auf der Zelloberfläche von Bakterien |
| US20040132634A1 (en) | 2001-01-31 | 2004-07-08 | Frank Sicheri | Compositions and methods for regulating the kinase domain of receptor tyrosine kinases |
| GB0110430D0 (en) | 2001-04-27 | 2001-06-20 | Medical Res Council | Protein variants and uses thereof |
| EP1737971B1 (en) | 2004-01-20 | 2017-08-16 | Merus N.V. | Mixtures of binding proteins |
| EP1778726A4 (en) * | 2004-08-16 | 2009-03-18 | Medimmune Inc | INTEGRIN ANTAGONISTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-ASSAYED CYTOTOXICITY ACTIVITY |
| WO2007100358A2 (en) | 2005-10-07 | 2007-09-07 | University Of Chicago | Convergent synthesis of proteins by kinetically controlled ligation |
| US7666622B2 (en) * | 2005-10-19 | 2010-02-23 | Regeneron Pharmaceuticals, Inc. | Monomeric self-associating fusion polypeptides and therapeutic uses thereof |
| WO2008045252A2 (en) | 2006-10-04 | 2008-04-17 | The Board Of Trustees Of The Leland Stanford Junior University | Engineered integrin binding peptides |
| EP1958957A1 (en) | 2007-02-16 | 2008-08-20 | NascaCell Technologies AG | Polypeptide comprising a knottin protein moiety |
| CA2692320A1 (en) * | 2007-07-02 | 2009-01-08 | Wyeth | Methods of treating bone disorders with modulators of axl |
| KR20100058509A (ko) | 2007-07-31 | 2010-06-03 | 메디뮨 엘엘씨 | 다중특이적 에피토프 결합 단백질 및 이의 용도 |
| WO2009097017A2 (en) * | 2007-09-18 | 2009-08-06 | The Jackson Laboratory | Antibodies and fc fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof |
| WO2009061853A2 (en) * | 2007-11-05 | 2009-05-14 | Massachusetts Institute Of Technology | Mutant interleukin-2 (il-2) polypeptides |
| EP2349327A4 (en) | 2008-10-23 | 2012-11-28 | Massachusetts Inst Technology | COMMITMENT DIRECTED FC RECEIVERS ACTIVATORS |
| US8329826B2 (en) | 2008-11-06 | 2012-12-11 | The Board Of Trustees Of The Leland Stanford Junior University | Surface modification of interpenetrating polymer networks |
| US8778888B2 (en) | 2009-11-06 | 2014-07-15 | The Board Of Trustees Of The Leland Stanford Junior University | Cystine knot peptides binding to alpha IIb beta 3 integrins and methods of use |
| PT2525824T (pt) | 2010-01-22 | 2017-07-13 | Univ Leland Stanford Junior | Inibição da sinalização de axl em terapêutica antimetastática |
| US10844106B2 (en) * | 2010-11-08 | 2020-11-24 | The Board Of Trustees Of The Leland Stanford Junior University | Fusion proteins comprising an engineered knottin peptide and uses thereof |
| US10350266B2 (en) * | 2017-01-10 | 2019-07-16 | Nodus Therapeutics, Inc. | Method of treating cancer with a multiple integrin binding Fc fusion protein |
-
2011
- 2011-11-07 US US13/883,216 patent/US10844106B2/en active Active
- 2011-11-07 EP EP19180924.3A patent/EP3604549A1/en not_active Withdrawn
- 2011-11-07 JP JP2013537908A patent/JP6170435B2/ja not_active Expired - Fee Related
- 2011-11-07 DK DK11839687.8T patent/DK2638173T3/da active
- 2011-11-07 AU AU2011326164A patent/AU2011326164B2/en not_active Ceased
- 2011-11-07 CA CA2817197A patent/CA2817197C/en active Active
- 2011-11-07 WO PCT/US2011/059599 patent/WO2012064658A1/en not_active Ceased
- 2011-11-07 EP EP11839687.8A patent/EP2638173B1/en active Active
-
2016
- 2016-08-04 AU AU2016210712A patent/AU2016210712B2/en not_active Ceased
-
2017
- 2017-04-13 JP JP2017079525A patent/JP6535361B2/ja not_active Expired - Fee Related
-
2018
- 2018-01-24 AU AU2018200587A patent/AU2018200587B2/en not_active Ceased
-
2020
- 2020-10-08 US US17/066,167 patent/US11498952B2/en active Active
-
2022
- 2022-11-14 US US18/055,297 patent/US12240882B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014504270A5 (https=) | ||
| Webster et al. | Brain penetration, target engagement, and disposition of the blood‐brain barrier‐crossing bispecific antibody antagonist of metabotropic glutamate receptor type 1 | |
| Reguera et al. | Structural bases of coronavirus attachment to host aminopeptidase N and its inhibition by neutralizing antibodies | |
| RU2769470C2 (ru) | Рекомбинантные связывающие белки и их применение | |
| Ebos et al. | A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma | |
| AU2013322628B2 (en) | Monoclonal antibodies to growth and differentiation factor 15 (GDF-15) | |
| Goodman et al. | Matched rabbit monoclonal antibodies against αv-series integrins reveal a novel αvβ3-LIBS epitope, and permit routine staining of archival paraffin samples of human tumors | |
| Anisimov et al. | Vascular endothelial growth factor-angiopoietin chimera with improved properties for therapeutic angiogenesis | |
| Sun et al. | Structural basis of antibody inhibition and chemokine activation of the human CC chemokine receptor 8 | |
| JP2021502063A5 (https=) | ||
| Low et al. | VHH antibody targeting the chemokine receptor CX3CR1 inhibits progression of atherosclerosis | |
| RU2018102798A (ru) | Антитела к фактору xi и способы их применения | |
| EA201290525A1 (ru) | Новые антитела-антагонисты, их fab-фрагменты против gpvi и способы их применения | |
| TW201906867A (zh) | 嵌合抗體免疫效應細胞接合物及其使用方法 | |
| Arcangeli et al. | The Junctional Adhesion Molecule-B regulates JAM-C-dependent melanoma cell metastasis | |
| JP2019514361A5 (https=) | ||
| ATE497508T1 (de) | Gegen das säugetier-eag1-ionenkanalprotein gerichtete antikörper | |
| CN110809580A (zh) | 用于靶向癌症中包含非典型hla-i和新抗原的复合体的方法和组合物 | |
| WO2007070671A3 (en) | Therapeutic methods for inhibiting tumor growth with dll4 antagonists | |
| Farrell et al. | The PfRCR complex bridges malaria parasite and erythrocyte during invasion | |
| EA201500204A1 (ru) | Антитела к ox40 и способы их применения | |
| JP2014530001A5 (https=) | ||
| US20150165065A1 (en) | Non-natural mic proteins | |
| JP2019122378A (ja) | ムスカリン性アセチルコリン受容体の結合剤およびそれらの使用 | |
| JP2017510627A5 (https=) |